Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 299

1.

Role of 18F-fluorodeoxyglucose positron emission tomography in predicting epidermal growth factor receptor mutations in non-small cell lung cancer.

Mak RH, Digumarthy SR, Muzikansky A, Engelman JA, Shepard JA, Choi NC, Sequist LV.

Oncologist. 2011;16(3):319-26. doi: 10.1634/theoncologist.2010-0300. Epub 2011 Feb 21.

2.

Metabolic phenotype of stage IV lung adenocarcinoma: relationship with epidermal growth factor receptor mutation.

Lee EY, Khong PL, Lee VH, Qian W, Yu X, Wong MP.

Clin Nucl Med. 2015 Mar;40(3):e190-5. doi: 10.1097/RLU.0000000000000684.

PMID:
25608155
3.

Role of [¹⁸F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer.

Caicedo C, Garcia-Velloso MJ, Lozano MD, Labiano T, Vigil Diaz C, Lopez-Picazo JM, Gurpide A, Zulueta JJ, Richter Echevarria JA, Perez Gracia JL.

Eur J Nucl Med Mol Imaging. 2014 Nov;41(11):2058-65. doi: 10.1007/s00259-014-2833-4. Epub 2014 Jul 3. Erratum in: Eur J Nucl Med Mol Imaging. 2014 Nov;41(11):2164. Zulueta, Javier [corrected to Zulueta, Javier J].

PMID:
24990403
4.

Correlation of F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value and EGFR mutations in advanced lung adenocarcinoma.

Huang CT, Yen RF, Cheng MF, Hsu YC, Wei PF, Tsai YJ, Tsai MF, Shih JY, Yang CH, Yang PC.

Med Oncol. 2010 Mar;27(1):9-15. doi: 10.1007/s12032-008-9160-1. Epub 2009 Jan 7.

PMID:
19130320
5.

Imaging characteristics of stage I non-small cell lung cancer on CT and FDG-PET: relationship with epidermal growth factor receptor protein expression status and survival.

Lee Y, Lee HJ, Kim YT, Kang CH, Goo JM, Park CM, Paeng JC, Chung DH, Jeon YK.

Korean J Radiol. 2013 Mar-Apr;14(2):375-83. doi: 10.3348/kjr.2013.14.2.375. Epub 2013 Feb 22.

6.

Revisiting the prognostic value of preoperative (18)F-fluoro-2-deoxyglucose ( (18)F-FDG) positron emission tomography (PET) in early-stage (I & II) non-small cell lung cancers (NSCLC).

Agarwal M, Brahmanday G, Bajaj SK, Ravikrishnan KP, Wong CY.

Eur J Nucl Med Mol Imaging. 2010 Apr;37(4):691-8. doi: 10.1007/s00259-009-1291-x. Epub 2009 Nov 14.

7.

Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.

Liao S, Penney BC, Wroblewski K, Zhang H, Simon CA, Kampalath R, Shih MC, Shimada N, Chen S, Salgia R, Appelbaum DE, Suzuki K, Chen CT, Pu Y.

Eur J Nucl Med Mol Imaging. 2012 Jan;39(1):27-38. doi: 10.1007/s00259-011-1934-6. Epub 2011 Sep 23.

PMID:
21946983
8.

18F-FDG uptake and EGFR mutations in patients with non-small cell lung cancer: a single-institution retrospective analysis.

Na II, Byun BH, Kim KM, Cheon GJ, Choe du H, Koh JS, Lee DY, Ryoo BY, Baek H, Lim SM, Yang SH, Kim CH, Lee JC.

Lung Cancer. 2010 Jan;67(1):76-80. doi: 10.1016/j.lungcan.2009.03.010.

PMID:
19371962
9.

(18)F-fluorodeoxyglucose positron emission tomography versus computed tomography in predicting histopathological response to epidermal growth factor receptor-tyrosine kinase inhibitor treatment in resectable non-small cell lung cancer.

van Gool MH, Aukema TS, Schaake EE, Rijna H, Codrington HE, Valdés Olmos RA, Teertstra HJ, van Pel R, Burgers SA, van Tinteren H, Klomp HM.

Ann Surg Oncol. 2014 Sep;21(9):2831-7. doi: 10.1245/s10434-014-3791-6. Epub 2014 May 21.

PMID:
24845729
10.

Predictive value of 18F-fluorodeoxyglucose uptake by positron emission tomography for non-small cell lung cancer patients treated with radical radiotherapy.

Ikushima H, Dong L, Erasmus J, Allen P, McAleer MF, Zhuang Y, Sasaki R, Komaki R.

J Radiat Res. 2010;51(4):465-71. Epub 2010 May 28.

11.

18F-FDG uptake for prediction EGFR mutation status in non-small cell lung cancer.

Guan J, Xiao NJ, Chen M, Zhou WL, Zhang YW, Wang S, Dai YM, Li L, Zhang Y, Li QY, Li XZ, Yang M, Wu HB, Chen LH, Liu LY.

Medicine (Baltimore). 2016 Jul;95(30):e4421. doi: 10.1097/MD.0000000000004421.

12.

FDG uptake in non-small cell lung cancer is not an independent predictor of EGFR or KRAS mutation status: a retrospective analysis of 206 patients.

Lee SM, Bae SK, Jung SJ, Kim CK.

Clin Nucl Med. 2015 Dec;40(12):950-8. doi: 10.1097/RLU.0000000000000975.

PMID:
26359571
13.

Value of ¹⁸F-FDG uptake on PET/CT and CEA level to predict epidermal growth factor receptor mutations in pulmonary adenocarcinoma.

Ko KH, Hsu HH, Huang TW, Gao HW, Shen DH, Chang WC, Hsu YC, Chang TH, Chu CM, Ho CL, Chang H.

Eur J Nucl Med Mol Imaging. 2014 Oct;41(10):1889-97. doi: 10.1007/s00259-014-2802-y. Epub 2014 May 23. Erratum in: Eur J Nucl Med Mol Imaging. 2014 Oct;41(10):1989-90.

PMID:
24852187
14.

CyberKnife radiosurgery for inoperable stage IA non-small cell lung cancer: 18F-fluorodeoxyglucose positron emission tomography/computed tomography serial tumor response assessment.

Vahdat S, Oermann EK, Collins SP, Yu X, Abedalthagafi M, Debrito P, Suy S, Yousefi S, Gutierrez CJ, Chang T, Banovac F, Anderson ED, Esposito G, Collins BT.

J Hematol Oncol. 2010 Feb 4;3:6. doi: 10.1186/1756-8722-3-6.

15.

Residual ¹⁸F-FDG-PET uptake 12 weeks after stereotactic ablative radiotherapy for stage I non-small-cell lung cancer predicts local control.

Bollineni VR, Widder J, Pruim J, Langendijk JA, Wiegman EM.

Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):e551-5. doi: 10.1016/j.ijrobp.2012.01.012. Epub 2012 Mar 13.

PMID:
22417800
16.

Limited predictive value of dual-time-point F-18 FDG PET/CT for evaluation of pathologic N1 status in NSCLC patients.

Kim SJ, Kim YK, Kim IJ, Kim YD, Lee MK.

Clin Nucl Med. 2011 Jun;36(6):434-9. doi: 10.1097/RLU.0b013e31820adef8.

PMID:
21552019
17.

Implications of false negative and false positive diagnosis in lymph node staging of NSCLC by means of ¹⁸F-FDG PET/CT.

Li S, Zheng Q, Ma Y, Wang Y, Feng Y, Zhao B, Yang Y.

PLoS One. 2013 Oct 25;8(10):e78552. doi: 10.1371/journal.pone.0078552. eCollection 2013.

18.

Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.

Zhang H, Wroblewski K, Liao S, Kampalath R, Penney BC, Zhang Y, Pu Y.

Acad Radiol. 2013 Jan;20(1):32-40. doi: 10.1016/j.acra.2012.07.002. Epub 2012 Sep 19.

PMID:
22999369
19.

[Density and SUV ratios from PET/CT in the detection of mediastinal lymph node metastasis in non-small cell lung cancer].

Shao T, Yu L, Li Y, Chen M.

Zhongguo Fei Ai Za Zhi. 2015 Mar;18(3):155-60. doi: 10.3779/j.issn.1009-3419.2015.03.05. Chinese.

20.

Ratio of standardized uptake value on PET helps predict response and outcome after chemotherapy in advanced non-small cell lung cancer.

Kaira K, Endo M, Asakura K, Tsuya A, Nakamura Y, Naito T, Murakami H, Takahashi T, Yamamoto N.

Ann Nucl Med. 2010 Dec;24(10):697-705. doi: 10.1007/s12149-010-0412-8. Epub 2010 Sep 8.

PMID:
20824397

Supplemental Content

Support Center